Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company, announced that CEO Mark Velleca will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY. The event, focusing on the company's development of MasterKey therapies for oncogenic mutations in cancer patients, is scheduled for June 5, 2024, from 7:30-7:55am ET. The presentation will be available via live webcast on the company's investor relations website, with a replay accessible for 90 days post-event.
- CEO participation at a prestigious conference like Jefferies Global Healthcare Conference.
- Company will present its innovative MasterKey therapies targeting oncogenic mutations.
- Event can increase investor interest and visibility for Black Diamond Therapeutics.
- Live webcast and 90-day replay availability increase accessibility for potential investors.
- No new clinical data or financial results announced in the press release.
- The event's short duration (25 minutes) may limit the depth of information shared.
- Potential lack of significant stock price impact if no major news or advancements are disclosed.
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY.
Presentation details are as follows:
- 7:30-7:55am ET on Wednesday, June 5
A live webcast of the event can be accessed by visiting the investors relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com
For Media:
media@bdtx.com
FAQ
What is the date and time of Black Diamond Therapeutics' presentation at the Jefferies Global Healthcare Conference?
Where can I watch the Black Diamond Therapeutics presentation at the Jefferies Global Healthcare Conference?
Who will represent Black Diamond Therapeutics at the Jefferies Global Healthcare Conference?
How long will the presentation replay be available?
What is the stock symbol for Black Diamond Therapeutics?
